Pharmanex red yeast "mutant" strain patent shows intent to enhance lovastatin -- Merck.
This article was originally published in The Tan Sheet
Executive Summary
PHARMANEX RED YEAST RICE PATENT APPLICATION DESCRIBING "MUTANT" STRAIN demonstrates the company's Cholestin dietary supplement is made of traditional red yeast rice that has been manipulated to ensure a substantial lovastatin content, Merck argues in May 5 comments to FDA. An international patent application filed by Pharmanex and Peking University Sept. 29 "makes clear that Cholestin is not traditional red yeast rice, or Hong Qu, and that the process for producing Cholestin has been modified to produce a new product enhanced for production of ingredients that lower cholesterol," Merck maintains.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning